Atara Biotherapeutics

Clinical Studies

Please contact us if you are interested in learning more about our ongoing clinical studies or check clinicaltrials.gov.

ATA3219

  • Phase
  • Trial Number
  • Trial Description
  • 1
  • NCT06256484
  • Phase 1 Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Subjects With Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma
  • 1
  • NCT06429800
  • Phase l Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Subjects With Lupus Nephritis

Tabelecleucel (tab‐cel®)

  • Phase
  • Trial Number
  • Trial Description
  • 3
  • NCT03394365
  • Tabelecleucel for Solid Organ Transplant (SOT) Subjects After Failure of Rituximab or Rituximab and Chemotherapy, and in Hematopoietic Cell Transplant (HCT) Subjects after Failure of Rituximab (ALLELE)
  • 2
  • NCT04554914
  • Phase 2 study to Evaluate Tabelecleucel in Subjects With Epstein-Barr Virus-associated Diseases

Requests for Expanded Access

Atara does not have an expanded access program at this time and participation in our clinical studies is the only way to access our investigational therapies.

View Policy

Enrollment

For more information on enrollment in our current clinical trials, please contact us or visit clinicaltrials.gov for location information.

The safety and efficacy of these investigational products have not been established. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.